Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2711453 | 0.91 | PIK3CA (0.60) | PIK3CDPIK3CAMAPK13MAPK12MAPK10 | |
| SCHEMBL2712032 | 0.91 | PIK3CD (0.51) | PIK3CDPIK3CAMAPK13MAPK12MAPK10 | |
| SCHEMBL3785567 | 0.89 | PIK3CD (0.54) | PIK3CDPIK3CA | |
| SCHEMBL2711467 | 0.88 | PIK3CA (0.58) | PIK3CDPIK3CA | |
| SCHEMBL2710728 | 0.87 | PIK3CD (0.54) | PIK3CDPIK3CA | |
| SCHEMBL13019230 | 0.86 | PIK3CA (0.58) | PIK3CDPIK3CA | |
| SCHEMBL2712603 | 0.86 | PIK3CD (0.60) | PIK3CDPIK3CA | |
| SCHEMBL2711307 | 0.85 | PIK3CD (0.70) | PIK3CDPIK3CA | |
| SCHEMBL2712545 | 0.85 | PIK3CD (0.52) | PIK3CDPIK3CA | |
| SCHEMBL2713852 | 0.85 | PIK3CD (0.52) | PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CD 14/4885PIK3CA 29/4885MAPK13 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.